苍耳桑梅方治疗过敏性鼻炎-哮喘综合征临床疗效评价

Evaluation of clinical efficacy for Canger Sangmei Formula in the treatment of combined allergic rhinitis and asthma syndrome

目的:评价苍耳桑梅方对过敏性鼻炎-哮喘综合征(CARAS)的临床疗效及安全性。方法:将入组的146例CARAS患者按照1∶1的比例随机分为对照组和治疗组,两组均进行规范化基础西医治疗,治疗组同时给予苍耳桑梅方中药颗粒剂口服,疗程为14 d。观察治疗前后症状评分、哮喘控制测试(ACT)评分、肺功能等结局指标及安全性指标。结果:治疗后治疗组总体疗效、症状总积分及多数单项症状积分、ACT评分及FEV1%pred与PEF%pred肺功能指标均显著优于对照组(P<0.01)。结论:苍耳桑梅方临床疗效确切,可明显改善CARAS症状和肺功能,且安全可靠。

Objective: To observe the therapeutic effect and safety of Canger Sangmei Formula in the treatment of combined allergic rhinitis and asthma syndrome(CARAS). Methods: A total of 146 patients with CARAS were randomly divided into control group and treatment group according to the ratio of 1∶1. Then both groups were treated with standardized basic western medicine, while the treatment group was given Canger Sangmei Formula granules orally, the duration of treatment is 14 days. Outcome indicators including the symptom score, ACT score, indexes of pulmonary function, and safety indicators were observed before and after treatment. Results: After treatmengt, the total curative effect, symptom total score, most single symptom score, ACT score, FEV1%pred and PEF%pred in the treatment group were significantly better than those in the control group(P<0.01). Conclusion: Canger Sangmei Formula is effective, safe and reliable in the treatment of CARAS, and can significantly improve symptoms and lung function.